Welcome to HitGen

News

Get up to date with the latest HitGen articles and join us in the events

  1. News
  2. Press Release

SEMINAR | Development of selective irreversible BTK inhibitor Release Time:2018-08-22

Abstract:

Bruton’s tyrosine kinase (BTK) is a member of the Tec tyrosine kinase family, which is expressed in most hematopoietic cells such as B cells, myeloid cell, mast cells, and macrophage. BTK is a kinase that plays a crucial role in B-cell signaling pathway, which is an important downstream mediator of NF-κB and MAPK signaling pathways, which are strongly associated with cancer.  Therefore, BTK is a promising biological target for therapeutic intervention of autoimmune diseases and cancer/B cell malignancies.


Biography:

Dr. Wang graduated from Tokyo Institute of Technology in 2006 with a doctoral degree in Biomolecular Engineering. After that, he worked as a Postdoctoral researcher in Japan and USA for 6 years. Dr. Wang is currently working as a senior director of medchem in a Pharmaceutical company in Peking now.


Questions?

For more details on how we can advance your innovative drug discovery projects
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information